The United Kingdom has added a new indication for Iluvien, approving it for the prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye, according to a press release from Alimera Sciences.
Two 3-year, double- masked, prospective, sham-controlled studies of Iluvien (fluocinolone acetonide intravitreal implant) support the new indication.
The PSV-FAI-001 study, which included 129 patients, found Iluvien to be superior to sham. At 24 months, 40.2% of eyes treated with Iluvien had no recurrence of symptoms compared with 2.4% of patients who were treated
Uncategorized